Biotech: Page 2
-
Alex Wong/Getty Images via Getty Images
Q&AFormer U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
By Michael Gibney • March 14, 2024 -
Michael M. Santiago via Getty Images
These biotech hotspots are ripe for IPOs
Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.
By Amy Baxter • March 13, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
Stock via Getty Images
As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
By Alexandra Pecci • March 12, 2024 -
Stock via Getty Images
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
By Michael Gibney • March 12, 2024 -
Stock via Getty Images
Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D
The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.
By Kelly Bilodeau • March 11, 2024 -
Scott Olson via Getty Images
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.
By Amy Baxter • March 11, 2024 -
Permission granted by Natalie Ferguson/American Gene Technologies
ProfileHIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
By Michael Gibney • March 5, 2024 -
Permission granted by Nasdaq, Inc.
Biotech IPOs heated up to start 2024. Will the surge last?
Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead.
By Gwendolyn Wu , Ben Fidler • March 5, 2024 -
Stock via Getty Images
Did the FTC get it wrong when it blocked the Sanofi-Maze deal?
In its zeal to stamp out anticompetitive practices and lower drug prices, a consultant said the FTC might have overlooked the unique considerations in rare disease drug development.
By Alexandra Pecci • March 4, 2024 -
Stock via Getty Images
Biotech SpotlightBlack Diamond looks to outwit cancer mutations
Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.
By Kelly Bilodeau • March 4, 2024 -
iStock via Getty Images
Q&ABiogen partner NeuroSense seeks a role in the ALS revolution
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
By Michael Gibney • Feb. 29, 2024 -
Permission granted by Lindus Health
Can a top scientist and Moderna co-founder change the CRO game?
From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.
By Michael Gibney • Feb. 28, 2024 -
Permission granted by Gianluca Pirozzi
ProfileBehind a big-name rare disease biotech, an exec draws from personal experience
The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.
By Alexandra Pecci • Feb. 27, 2024 -
ismagilov via Getty Images
BioMarin preaches patience amid slow sales for hemophilia gene therapy
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
By Ben Fidler • Feb. 23, 2024 -
Permission granted by Ferring Pharmaceuticals
Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health
Ferring’s U.S. president Brent Ragans discusses the company’s strategy as it expands into new therapeutic areas and further develops its reproductive pipeline.
By Alexandra Pecci • Feb. 22, 2024 -
Stock via Getty Images
4 biotechs to watch in 2024
A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.
By Alexandra Pecci • Feb. 21, 2024 -
Permission granted by Iovance Biotherapeutics
Behind the breakthrough cancer therapy that just won a historic FDA nod
The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.
By Kelly Bilodeau • Feb. 21, 2024 -
Courtesy of Biogen
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.
By Michael Gibney • Feb. 15, 2024 -
iStock via Getty Images
These 4 drugs had tons of promise — and they flopped. What happened?
No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.
By Alexandra Pecci • Feb. 13, 2024 -
iStock via Getty Images
A new (old) mind-opening tool in the fight against Alzheimer’s disease
A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.
By Kelly Bilodeau • Feb. 12, 2024 -
iStock via Getty Images
Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps
While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.
By Michael Gibney • Feb. 8, 2024 -
Getty Images via Getty Images
‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap
The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.
By Michael Gibney • Feb. 6, 2024 -
Stock via Getty Images
Vaxxinity is brewing up meds for a spacefaring future
The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.
By Kelly Bilodeau • Feb. 5, 2024 -
Ricardo Ceppi via Getty Images
Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name
Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.
By Alexandra Pecci • Jan. 30, 2024 -
Permission granted by Bristol-Myers Squibb
CAR-T developers respond to FDA black box warning
Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.
By Kelly Bilodeau • Jan. 30, 2024
Previous
